(2-carboxamido)(3-amino)thiophene compounds

1. A compound represented by Formula (I):

or a pharmaceutically acceptable salt or N-oxide thereof, wherein

R1 is

R2 is

 and

R3 is C 0-4 alkyl.

2. The compound according to claim 1 , or a pharmaceutically acceptable salt or N-oxide thereof, wherein R2 is

3. The compound according to claim 1 , or a pharmaceutically acceptable salt or N-oxide thereof, wherein R2 is

and R3 is hydrogen.

4. The compound according to claim 1 , or a pharmaceutically acceptable salt or N-oxide thereof, wherein R2 is

5. The compound according to claim 1 , or a pharmaceutically acceptable salt or N-oxide thereof, wherein R2 is

and R3 is hydrogen.

6. The compound according to claim 1 , or a pharmaceutically acceptable salt or N-oxide thereof, wherein R2 is

7. The compound according to claim 1 , or a pharmaceutically acceptable salt or N-oxide thereof, wherein R2 is

and R3 is C 0-4 alkyl.

8. The compound according to claim 1 , or a pharmaceutically acceptable salt or N-oxide thereof, wherein R2 is

and R3 is hydrogen.

9. The compound according to claim 1 , or a pharmaceutically acceptable salt or N-oxide thereof, wherein R2 is

and R3 is C 0-4 alkyl.

10. A composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt or N-oxide thereof, and a pharmaceutically acceptable carrier.

11. A composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt or N-oxide thereof; and

an anti-neoplastic, anti-tumor, anti-angiogenic, or chemotherapeutic agent.

12. A composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt or N-oxide thereof, and a cytotoxic cancer therapeutic agent.

13. A composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt or N-oxide thereof, and an angiogenesis inhibiting cancer therapeutic agent.

14. A compound consisting of

N-(4-trifluoromethoxyphenyl) 3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;

N-(4-bromo-3-methylphenyl) 3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;

N-(2,2,3,3-tetrafluorobenzodioxan-6-yl) 3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;

N-(4-chlorophenyl) 3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;

4-{[2-(4-bromo-3-methylphenylcarbamoyl)thiophen-3-ylamino]methyl}pyridine-2-carboxylic acid methylamide;

4-{[2-(2,2,3,3-tetrafluorobenzodioxan-6-ylcarbamoyl)thiophen-3-ylamino]methyl}pyridine-2-carboxylic acid methylamide;

4-{[2-(4-chlorophenylcarbamoyl)thiophen-3-ylamino]methyl}pyridine-2-carboxylic acid methylamide;

N-(4-chlorophenyl) 3-[(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)amino]thiophene-2-carboxamide;

N-(4-bromo-3-methylphenyl) 3-[(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)amino]thiophene-2-carboxamide;

N-(2,2,3,3-tetrafluorobenzodioxan-6-yl) 3-[(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)amino]thiophene-2-carboxamide;

N-{[2-(4-trifluoromethoxyphenylcarbamoyl)thiophen-3-ylamino]methyl}pyridine-2-carboxylic acid methylamide; and

N-(4-Trifluoromethoxy)phenyl-3-[(1H-pyrrolo[2,3-b]pyridin-4-ylmethyl)amino]thiophene-2-carboxamide;

N-(4-chlorophenyl)-3-[(1H-pyrrolo[2,3-b]pyridin-4-ylmethyl)amino]thiophene-2-carboxamide;

3-[(1H-pyrrolo[2,3-b]pyridin-4-ylmethyl)amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)thiophene-2-carboxamide;

4-Methyl-N-(4-trifluoromethoxyphenyl)phenyl-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;

N-(4-chlorophenyl)-4-methyl-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;

N-(4-bromo-3-methylphenyl)-4-methyl-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;

4-Methyl-3-[(quinolin-4-ylmethyl)amino]-N-(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)thiophene-2-carboxamide;

3-{[(1-oxidoquinolin-4-yl)methyl]amino}-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide

or a pharmaceutically acceptable salt, or N-oxide, thereof.

15. A method of treatment of hyperproliferative disorder comprising a step of administering an effective amount of the compound according to claim 1 wherein the hyperproliferative disorder is selected from the group consisting of breast cancer, head cancer, neck cancer, gastrointestinal cancer, leukemia, ovarian, bronchial, lunch or pancreatic cancer.

16. The method of claim 15 wherein the hyperproliferative disorder is sinonasal natural killer/T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, adenoid cystic carcinoma, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, or prostate carcinoma.